Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Vilde Yuli Stenberg"'
Autor:
Asta Juzeniene, Vilde Yuli Stenberg, Øyvind Sverre Bruland, Mona-Elisabeth Revheim, Roy Hartvig Larsen
Publikováno v:
Frontiers in Medicine, Vol 9 (2023)
Metastases are the primary cause of death among cancer patients and efficacious new treatments are sorely needed. Targeted alpha-emitting radiopharmaceuticals that are highly cytotoxic may fulfill this critical need. The focus of this paper is to des
Externí odkaz:
https://doaj.org/article/d7c8d3316aea442f97f2e4ac8628bf55
Autor:
Anna Julie Kjøl Tornes, Vilde Yuli Stenberg, Roy Hartvig Larsen, Øyvind Sverre Bruland, Mona-Elisabeth Revheim, Asta Juzeniene
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Osteosarcoma patients with overt metastases at primary diagnosis have a 5-year survival rate of less than 20%. TP-3 is a murine IgG2b monoclonal antibody with high affinity for an epitope residing on the p80 osteosarcoma cell surface membrane antigen
Externí odkaz:
https://doaj.org/article/08e58ac533f34f7f8cbefaa9a9134bae
The feasibility, performance, and radiation safety of an experimental generator were evaluated to efficiently produce 212Pb intended for radiopharmaceuticals. Methods: The generator consisted of a flask with a removable cap containing a source of 224
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7561146a98301714ee028e28292194ac
http://hdl.handle.net/10852/101316
http://hdl.handle.net/10852/101316
Autor:
Vilde Yuli Stenberg, Roy H. Larsen, Asta Juzeniene, Øyvind S. Bruland, Xiaoming Yang, Qingqi Chen
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 63:129-143
Prostate-specific membrane antigen (PSMA) is the most promising target for radioligand therapy of prostate cancer. The aim of this study was to prepare a small molecular ligand p-SCN-Bn-TCMC-PSMA (NG001) and compare it with the commonly used DOTA-bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d72021bd7fc67794d843a78891f75ac6
https://doi.org/10.1002/jlcr.3825
https://doi.org/10.1002/jlcr.3825
Autor:
Vilde Yuli, Stenberg, Anna Julie Kjøl, Tornes, Hogne Røed, Nilsen, Mona-Elisabeth, Revheim, Øyvind Sverre, Bruland, Roy Hartvig, Larsen, Asta, Juzeniene
Publikováno v:
Cancers. 14(11)
This study aimed to determine the influence of cellular PSMA expression, radioligand binding and internalization, and repeated administrations on the therapeutic effects of the PSMA-targeting radioligand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::390832c1cf26bd18faf300b9f7453533
https://pubmed.ncbi.nlm.nih.gov/35681766
https://pubmed.ncbi.nlm.nih.gov/35681766
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
The feasibility, performance, and radiation safety of a novel generator were evaluated to efficiently produce ¬212Pb intended for radiopharmaceuticals.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::361755f39bba1bcd9e93b14070e530e4
https://pubmed.ncbi.nlm.nih.gov/35798556
https://pubmed.ncbi.nlm.nih.gov/35798556
Autor:
Vilde Yuli, Stenberg, Roy Hartvig, Larsen, Li-Wei, Ma, Qian, Peng, Petras, Juzenas, Øyvind Sverre, Bruland, Asta, Juzeniene
Publikováno v:
International Journal of Molecular Sciences
Radioligand therapy targeting the prostate-specific membrane antigen (PSMA) is rapidly evolving as a promising treatment for metastatic castration-resistant prostate cancer. The PSMA-targeting ligand p-SCN-Bn-TCMC-PSMA (NG001) labelled with 212Pb eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7e0d81d1aaa9d5934abd6634f46bb93d
https://pubmed.ncbi.nlm.nih.gov/34062920
https://pubmed.ncbi.nlm.nih.gov/34062920
Publikováno v:
Cancers, Vol 13, Iss 779, p 779 (2021)
Cancers
Cancers
Simple Summary Currently, there is no treatment that can cure patients with late stage metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein overexpressed on the membrane surface of most prostate cancer cells. The precli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4487ebd3b9ef4d67ef2eabc05dcee890
https://pubmed.ncbi.nlm.nih.gov/33668474
https://pubmed.ncbi.nlm.nih.gov/33668474
Autor:
Vilde Yuli, Stenberg, Asta, Juzeniene, Qingqi, Chen, Xiaoming, Yang, Øyvind Sverre, Bruland, Roy Hartvig, Larsen
Publikováno v:
Journal of labelled compoundsradiopharmaceuticalsREFERENCES. 63(3)
Prostate-specific membrane antigen (PSMA) is the most promising target for radioligand therapy of prostate cancer. The aim of this study was to prepare a small molecular ligand p-SCN-Bn-TCMC-PSMA (NG001) and compare it with the commonly used DOTA-bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::27337fa1113a5bf2544a28351cb06e2f
https://pubmed.ncbi.nlm.nih.gov/31919866
https://pubmed.ncbi.nlm.nih.gov/31919866
Autor:
Øyvind S. Bruland, Roy H. Larsen, Asta Juzeniene, Petras Juzenas, Li-Wei Ma, Qian Peng, Vilde Yuli Stenberg
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 4815, p 4815 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 9
International Journal of Molecular Sciences
Volume 22
Issue 9
Radioligand therapy targeting the prostate-specific membrane antigen (PSMA) is rapidly evolving as a promising treatment for metastatic castration-resistant prostate cancer. The PSMA-targeting ligand p-SCN-Bn-TCMC-PSMA (NG001) labelled with 212Pb eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75dc0092742fd4f4e49408572758d81a
https://doi.org/10.3390/ijms22094815
https://doi.org/10.3390/ijms22094815